Effects of thiazolidinedione in patients with active bladder cancer.

Roger LiMichael J MetcalfeJames E FergusonSharada MokkapatiGraciela M Nogueras GonzálezColin P DinneyNeema NavaiDavid J McConkeySunil K SahaiAshish M Kamat

Published in: BJU international (2017)

CSS, as well as RFS and OS after RC were not compromised in patients on TZD therapy at the time of RC. Additional investigation is warranted in patients with non-muscle-invasive bladder cancer and muscle-invasive bladder cancer undergoing bladder-sparing procedures to assess the safety of using TZD in the setting of active UC.

Keyphrases

muscle invasive bladder cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
spinal cord injury
prognostic factors
peritoneal dialysis
stem cells
bone marrow
mesenchymal stem cells
cell therapy